ATE488584T1 - Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften - Google Patents

Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften

Info

Publication number
ATE488584T1
ATE488584T1 AT00929588T AT00929588T ATE488584T1 AT E488584 T1 ATE488584 T1 AT E488584T1 AT 00929588 T AT00929588 T AT 00929588T AT 00929588 T AT00929588 T AT 00929588T AT E488584 T1 ATE488584 T1 AT E488584T1
Authority
AT
Austria
Prior art keywords
domains
generating
materials
binding properties
customized
Prior art date
Application number
AT00929588T
Other languages
English (en)
Inventor
Kalle Saksela
Marita Hiipakka
Original Assignee
Next Biomed Technologies Nbt Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next Biomed Technologies Nbt Oy filed Critical Next Biomed Technologies Nbt Oy
Application granted granted Critical
Publication of ATE488584T1 publication Critical patent/ATE488584T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Graft Or Block Polymers (AREA)
  • Ceramic Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00929588T 1999-05-26 2000-05-26 Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften ATE488584T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13608599P 1999-05-26 1999-05-26
PCT/FI2000/000477 WO2000072742A2 (en) 1999-05-26 2000-05-26 Methods and materials for generating sh3 domains with tailored binding properties

Publications (1)

Publication Number Publication Date
ATE488584T1 true ATE488584T1 (de) 2010-12-15

Family

ID=22471216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929588T ATE488584T1 (de) 1999-05-26 2000-05-26 Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften

Country Status (9)

Country Link
US (1) US6794144B1 (de)
EP (1) EP1181358B1 (de)
JP (1) JP2003500080A (de)
AT (1) ATE488584T1 (de)
AU (1) AU4761100A (de)
CA (1) CA2374180C (de)
DE (1) DE60045243D1 (de)
ES (1) ES2371464T3 (de)
WO (1) WO2000072742A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109532C1 (de) * 2001-02-28 2002-06-13 Matthias Geyer Fusionsprotein zum Blocken des HIV Nef-Proteins
EP1377828A4 (de) * 2001-04-10 2006-11-15 Childrens Medical Center Verfahren zur analyse und markierung von protein-protein-wechselwirkungen
WO2006068768A2 (en) * 2004-11-24 2006-06-29 Hanna Skubatch Methods and compositions for treating conditions
US7557088B2 (en) * 2006-03-28 2009-07-07 Neopro Labs, Llc Methods and compositions for treating conditions
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
US8217141B2 (en) * 2007-05-17 2012-07-10 Neopro Labs, Llc Crystalline and amorphous forms of peptide
US20090069237A1 (en) * 2007-07-18 2009-03-12 Hanna Skubatch Methods and compositions for treating conditions
JP6809789B2 (ja) 2013-01-17 2021-01-06 メディツィーニシェ・ホーホシューレ・ハノーファーＭｅｄｉｚｉｎｉｓｃｈｅ Ｈｏｃｈｓｃｈｕｌｅ Ｈａｎｎｏｖｅｒ 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
AU2015371265B2 (en) 2014-12-24 2021-06-03 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1)
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
MX2018006194A (es) 2015-11-19 2018-12-06 Asclepix Therapeutics Llc Peptidos con propiedades antiangiogenicas, antilinfangiogenicas y antiedemicas y formulaciones de nanoparticulas.
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP4276114A3 (de) 2016-03-07 2024-02-21 Vib Vzw Einzeldomänenantikörper gegen cd20
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
US11236141B2 (en) 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
MX2019003895A (es) 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン－ガンマおよびその使用
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2019028427A1 (en) 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
CN112074267B (zh) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 成纤维细胞结合剂及其用途
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
TW202228775A (zh) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
WO2023089243A1 (en) * 2021-11-19 2023-05-25 Pandemblock Oy Sh3 domain derivatives targeting receptor binding domain (rbd) of sars-cov-2 spike protein
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
EP4626933A1 (de) 2022-11-30 2025-10-08 Integral Molecular, Inc. Gegen claudin 6 gerichtete antikörper mit bispezifischen formaten davon
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750630A4 (de) 1994-03-11 1998-01-07 Ariad Pharma Inc Methode und materialien zur identifizierung von inhibitoren der molekularen interaktionen, welche durch die sh3 domänen vermittelt werden
DE69534920T2 (de) 1994-07-22 2007-04-05 University Of North Carolina Src SH3 BINDENDE PEPTIDE UND VERFAHREN ZU IHRER ISOLIERUNG UND VERWENDUNG
WO1996031625A1 (en) * 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same

Also Published As

Publication number Publication date
WO2000072742A2 (en) 2000-12-07
CA2374180C (en) 2012-09-11
DE60045243D1 (de) 2010-12-30
US6794144B1 (en) 2004-09-21
ES2371464T3 (es) 2012-01-03
EP1181358B1 (de) 2010-11-17
EP1181358A2 (de) 2002-02-27
AU4761100A (en) 2000-12-18
JP2003500080A (ja) 2003-01-07
CA2374180A1 (en) 2000-12-07
WO2000072742A3 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
DE60045243D1 (de) VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN
DE69839451D1 (de) Prozess zur herstellung und anwendung von anionischen lehm materialien
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
AU2002305450A1 (en) Proteomimetic compounds and methods
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
TW200603830A (en) Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
MY150237A (en) Cripto blocking antibodies and uses thereof
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
GR3035717T3 (en) Tie-2 ligands, methods of making and uses thereof
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
DE3280479D1 (de) Rekombinante DNS-Mittel und Verfahren
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EP1064308A4 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
PT1157042E (pt) Produção de anticorpos tetravalentes
NO903059L (no) Ligander og reseptorer omfattende nevnte ligander, fremgangsmaate for deres fremstilling og anvendelse.
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE60016461D1 (de) Verfahren zur behandlung von glassubstraten und glassubstraten zur herstellung von anzeigeschirmen
DE69940206D1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
ATE495193T1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
ATE501730T1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
ATE347536T1 (de) Chlorsilanblends zur behandlung von quarzfuellstoffen
DE69514415D1 (de) Verfahren zur Herstellung von Dioxazinverbindungen,damit gefärbte Materialien und Dioxazinverbindungen mit plattenartiger Kristallform.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties